After outlasting rival suitors J&J and Sanofi in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.
After outlasting rival suitors J&J and Sanofi in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.
Copyright © 2021 Biotech Networks, LLC